Possible modifications to further enhance activity of CD30-directed CAR-T cells include: 1) the identification of the ideal lymphodepleting regimen, 2) improvement in migration of CAR-T cells to the tumor site, 3) combination with novel therapies, such as checkpoint inhibitors or further engineering. The gene discussed is TNFRSF8; the disease is neoplasm.